Literature DB >> 25237909

Luteolin and Gemcitabine Protect Against Pancreatic Cancer in an Orthotopic Mouse Model.

Jodee L Johnson1, Vermont P Dia, Matthew Wallig, Elvira Gonzalez de Mejia.   

Abstract

OBJECTIVE: This study aimed to evaluate the ability of luteolin (Lut), gemcitabine (Gem), and their combination (Lut + Gem) to prevent the growth of pancreatic tumors in vivo.
METHODS: The antitumor effect of intraperitoneally administered Lut, Gem, and Lut + Gem was evaluated using an orthotopic mouse model for 6 weeks. Tumor growth after injection of human pancreatic cancer cells was assessed by measuring pancreatic tumor mass. The mechanism of action of antitumor effect was assessed by immunohistochemistry and Western blot procedures.
RESULTS: Luteolin + Gem significantly lowered (P = 0.048) the pancreatic tumor mass compared with control. Luteolin, Gem, and Lut + Gem significantly reduced the proliferating cell nuclear antigen expression (25%, 37%, and 37%, respectively). Luteolin + Gem treatment led to a significant reduction in the expressions of K-ras (46%, P = 0.0006), GSK-3β (34%, P = 0.014), P(Tyr216)GSK-3β (16%, P = 0.033), P(Ser311)NF-κB p65 (27%, P = 0.036), and bcl-2/bax ratio (68%, P = 0.006) while significantly increasing the expressions of cytochrome c (44%, P = 0.035) and caspase 3 (417%, P = 0.003).
CONCLUSIONS: Luteolin + Gem promoted apoptotic cell death in pancreatic tumor cells in vivo through inhibition of the K-ras/GSK-3β/NF-κB signaling pathway, leading to a reduction in the Bcl-2/Bax ratio, release of cytochrome c, and activation of caspase 3.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25237909     DOI: 10.1097/MPA.0000000000000215

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  9 in total

Review 1.  Luteolin and cancer metastasis suppression: focus on the role of epithelial to mesenchymal transition.

Authors:  Yaseen Hussain; Jing Hao Cui; Haroon Khan; Michael Aschner; Gaber El-Saber Batiha; Philippe Jeandet
Journal:  Med Oncol       Date:  2021-05-05       Impact factor: 3.064

2.  Exploration of the System-Level Mechanisms of the Herbal Drug FDY003 for Pancreatic Cancer Treatment: A Network Pharmacological Investigation.

Authors:  Ho-Sung Lee; In-Hee Lee; Kyungrae Kang; Sang-In Park; Minho Jung; Seung Gu Yang; Tae-Wook Kwon; Dae-Yeon Lee
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-10       Impact factor: 2.650

Review 3.  Glycogen synthase kinase-3β: a novel therapeutic target for pancreatic cancer.

Authors:  Li Ding; Daniel D Billadeau
Journal:  Expert Opin Ther Targets       Date:  2020-03-21       Impact factor: 6.902

4.  DPYD, down-regulated by the potentially chemopreventive agent luteolin, interacts with STAT3 in pancreatic cancer.

Authors:  Hiroyuki Kato; Aya Naiki-Ito; Shugo Suzuki; Shingo Inaguma; Masayuki Komura; Kenju Nakao; Taku Naiki; Kenta Kachi; Akihisa Kato; Yoichi Matsuo; Satoru Takahashi
Journal:  Carcinogenesis       Date:  2021-07-16       Impact factor: 4.944

Review 5.  Phytochemicals as Innovative Therapeutic Tools against Cancer Stem Cells.

Authors:  Emanuele-Salvatore Scarpa; Paolino Ninfali
Journal:  Int J Mol Sci       Date:  2015-07-10       Impact factor: 5.923

Review 6.  Dietary Polyphenols in Cancer Chemoprevention: Implications in Pancreatic Cancer.

Authors:  Anita Thyagarajan; Andrew S Forino; Raymond L Konger; Ravi P Sahu
Journal:  Antioxidants (Basel)       Date:  2020-07-23

Review 7.  Paving Luteolin Therapeutic Potentialities and Agro-Food-Pharma Applications: Emphasis on In Vivo Pharmacological Effects and Bioavailability Traits.

Authors:  Yasaman Taheri; Javad Sharifi-Rad; Gizem Antika; Yakup Berkay Yılmaz; Tugba Boyunegmez Tumer; Sawsan Abuhamdah; Subhash Chandra; Sarla Saklani; Ceyda Sibel Kılıç; Simona Sestito; Sevgi Durna Daştan; Manoj Kumar; Mohammed M Alshehri; Simona Rapposelli; Natália Cruz-Martins; William C Cho
Journal:  Oxid Med Cell Longev       Date:  2021-09-20       Impact factor: 6.543

Review 8.  Recent updates on anticancer mechanisms of polyphenols.

Authors:  Eshita Sharma; Dharam Chand Attri; Priyanka Sati; Praveen Dhyani; Agnieszka Szopa; Javad Sharifi-Rad; Christophe Hano; Daniela Calina; William C Cho
Journal:  Front Cell Dev Biol       Date:  2022-09-29

9.  Luteolin decreases invasiveness, deactivates STAT3 signaling, and reverses interleukin-6 induced epithelial-mesenchymal transition and matrix metalloproteinase secretion of pancreatic cancer cells.

Authors:  Xince Huang; Shengjie Dai; Juji Dai; Yuwu Xiao; Yongyu Bai; Bicheng Chen; Mengtao Zhou
Journal:  Onco Targets Ther       Date:  2015-10-19       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.